<DOC>
	<DOCNO>NCT00288197</DOCNO>
	<brief_summary>To evaluate efficacy safety voriconazole Chinese patient proven probable deep tissue fungal infection .</brief_summary>
	<brief_title>A Study To Assess The Efficacy And Safety Of Voriconazole In Chinese Patients With Serious Deep Tissue Fungal Infections</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Voriconazole</mesh_term>
	<criteria>Subjects proven probable invasive fungal infection include subject fail respond , intolerance approve antifungal treatment approval salvage treatment Principal Investigator Pfizer . Subjects show continue improvement antifungal agent , include amphotericin B , itraconazole , nystatin , fluconazole , flucytosine miconazole . Subjects invasive fungal infection cause fungus ( Mucor ) antifungal spectrum voriconazole .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2008</verification_date>
</DOC>